National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Bristol, UK; Central Finland Health Care District Hospital District, Department of Medicine, Finland District, Jyväskylä, Finland; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
Nutr Metab Cardiovasc Dis. 2022 Aug;32(8):1924-1935. doi: 10.1016/j.numecd.2022.05.005. Epub 2022 May 20.
Serum copper (Cu) and zinc (Zn) may play a role in the development of adverse cardiovascular outcomes including heart failure (HF). Serum Cu/Zn-ratio has been shown to be a risk indicator for cardiovascular disease, but its relationship with HF has not been previously investigated. We aimed to assess the association between Cu/Zn-ratio and incident HF risk using a prospective cohort study.
Study participants were recruited in eastern Finland with baseline examinations carried out between March 1998 and December 2001. Serum levels of Cu and Zn were measured using atomic absorption spectrometry in 1866 men aged 42-61 years without a history of HF at baseline. Multivariable-adjusted hazard ratios (HRs) with confidence intervals (CIs) were calculated for incident HF. During 26.5 years median follow-up, 365 HF cases occurred. Restricted cubic splines suggested linear relationships of serum Cu/Zn-ratio, Cu and Zn with HF risk. A unit increase in Cu/Zn-ratio was associated with an increased HF risk in analysis adjusted for several potential confounders including nutritional factors such as total energy intake, intake of fruits, berries and vegetables, and red meat (HR 1.63; 95% CI 1.06-2.51). The corresponding multivariable-adjusted HRs (95% CIs) for serum Cu and Zn were 2.42 (1.32-4.44) and 1.34 (0.50-3.63), respectively. Addition of Cu/Zn-ratio to a HF risk prediction model was associated with improved risk prediction.
In middle-aged and older Finnish men, increased serum Cu/Zn-ratio is associated with an increased risk of HF in a linear dose-response fashion and might improve HF risk assessment.
血清铜(Cu)和锌(Zn)可能在包括心力衰竭(HF)在内的不良心血管结局的发展中发挥作用。已经表明血清 Cu/Zn-比值是心血管疾病的风险指标,但它与 HF 的关系尚未得到研究。我们旨在使用前瞻性队列研究评估 Cu/Zn-比值与 HF 风险之间的关系。
研究参与者是在芬兰东部招募的,基线检查于 1998 年 3 月至 2001 年 12 月之间进行。在基线时,对 1866 名年龄在 42-61 岁之间且无 HF 病史的男性使用原子吸收光谱法测量血清 Cu 和 Zn 水平。使用多变量调整后的风险比(HR)及其置信区间(CI)计算 HF 的发生率。在 26.5 年的中位随访期间,发生了 365 例 HF 病例。受限立方样条表明血清 Cu/Zn-比值、Cu 和 Zn 与 HF 风险之间存在线性关系。在分析中,对几种潜在的混杂因素(包括总能量摄入、水果、浆果和蔬菜以及红肉的摄入量等营养因素)进行了调整后,Cu/Zn-比值每增加一个单位,HF 风险就会增加(HR 1.63;95%CI 1.06-2.51)。血清 Cu 和 Zn 的相应多变量调整后的 HR(95%CI)分别为 2.42(1.32-4.44)和 1.34(0.50-3.63)。将 Cu/Zn-比值添加到 HF 风险预测模型中与改善风险预测相关。
在中年和老年芬兰男性中,血清 Cu/Zn-比值增加与 HF 风险呈线性剂量反应关系,并且可能改善 HF 风险评估。